Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more
Integragen (ALINT) - Total Liabilities
Latest total liabilities as of June 2025: €3.26 Million EUR
Based on the latest financial reports, Integragen (ALINT) has total liabilities worth €3.26 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Integragen - Total Liabilities Trend (2008–2024)
This chart illustrates how Integragen's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Integragen Competitors by Total Liabilities
The table below lists competitors of Integragen ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rochester Resources Ltd
PINK:RCTFF
|
USA | $49.35 Million |
|
MT Educare Limited
NSE:MTEDUCARE
|
India | ₹2.67 Billion |
|
Cannabis Suisse Corp
PINK:CSUI
|
USA | $2.28 Million |
|
ELISA (EIA.SG)
STU:EIA
|
Germany | €1.98 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Integragen's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Integragen's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Integragen (2008–2024)
The table below shows the annual total liabilities of Integragen from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.76 Million | -37.24% |
| 2023-12-31 | €5.99 Million | -12.21% |
| 2022-12-31 | €6.82 Million | -8.03% |
| 2021-12-31 | €7.42 Million | +11.55% |
| 2020-12-31 | €6.65 Million | +56.88% |
| 2019-12-31 | €4.24 Million | -26.77% |
| 2018-12-31 | €5.79 Million | +22.68% |
| 2017-12-31 | €4.72 Million | -25.18% |
| 2016-12-31 | €6.31 Million | +10.91% |
| 2015-12-31 | €5.69 Million | +5.16% |
| 2014-12-31 | €5.41 Million | +6.20% |
| 2013-12-31 | €5.09 Million | +10.30% |
| 2012-12-31 | €4.62 Million | +19.14% |
| 2011-12-31 | €3.87 Million | +27.16% |
| 2010-12-31 | €3.05 Million | +4.81% |
| 2009-12-31 | €2.91 Million | +38.75% |
| 2008-12-31 | €2.10 Million | -- |